VerifyNow IIb/IIIa Assay
Description:The VerifyNow
IIb/IIIa Assay is an automated, turbidimetric, whole- blood assay designed to assess platelet function based upon the ability of activated platelets to bind to fibrinogen coated beads. The detection well of the VerifyNow
IIb/IIIa assay device contains all of the necessary reagents to perform this analysis. Within the well is an activator that induces the platelet to change the confo...
Company:Accumetrics
YM BioSciences Announces Secondary Efficacy and Safety Findings in
Randomized Phase IIB Aerolef Trial
- Company Announces Lead Investigator for U.S. Trial - MISSISSAUGA, ON, July 11, 2007 /PRNewswire-FirstCall/ - YMBioSciences Inc. , an oncology company that identifies, developsand commercializes differentiated products for patients worldwide,today announced results of secondary endpoint data from its 99patient, randomized, placebo-controlled, multi-center Phase
IIbtrial (DLXLEF-AP4) with...
Phase IIIb Clinical Data Validate the Overall and Cardiovascular
Safety Profile of Cycloset (A Quick Release Formulation of
Bromocriptine Mesylate) in Patients with Type 2 Diabetes
Data Also Support Drug's Efficacy at Improving Glycemic Control andReducing Diabetic Cardiovascular Complications CHICAGO, Ill., June 23, 2007 /PRNewswire/ -- VeroScience, LLC,in conjunction with its commercialization partner S2 Therapeutics,Inc., reported today the results of its Phase I
IIb clinical trialsupporting the overall and cardiovascular safety of Cycloset(TM) (Aquick release for...
Antisense Pharma: Promising Phase IIb Results of Targeted Therapy
with AP 12009 in Recurrent Anaplastic Astrocytoma
CHICAGO and REGENSBURG - June 21, 2007 - “In anaplasticastrocytoma, AP 12009 as a monotherapy is actually clearly superiorto temozolomide,” Prof. Albert Wong, M.D., StanfordUniversity, California, U.S.A. commented on the international Phase
IIb study with the TGF-beta 2-inhibitor AP 12009, under developmentby Antisense Pharma. Prof. Wong discussed the results of the studyin th...
ISTA Pharmaceuticals Announces Positive Preliminary Results from
Ecabet Sodium Phase IIb Study
- Pending Final Analysis of the Results, ISTA Plans to InitiatePhase III Studies in Dry Eye in 2008 - IRVINE, Calif., May 31, 2007 /PRNewswire-FirstCall/ -- ISTAPharmaceuticals, Inc. , today announced positive results from thepreliminary analysis of the Company's Phase
IIb clinical study ofecabet sodium, which is being developed as a treatment for dry eyesyndrome. Patients in the ecabet s...
Alexza Pharmaceuticals to Present AZ-001 Phase IIb Clinical Data at
the American Headache Society Meeting
PALO ALTO, Calif., May 31, 2007 /PRNewswire-FirstCall/ -- AlexzaPharmaceuticals, Inc. announced today that it will present at the49th Annual American Headache Society Meeting the results of aPhase
IIb clinical trial of Staccato(R) prochlorperazine (AZ-001)for the acute treatment of migraine headache. The posterpresentation, "Efficacy and tolerability profile of AZ-001(Staccato prochlorpe...
More>>